We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA

06.03.13


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles
ASCO 2013: Dr. Ander...
ASCO 2013: Dr. Jagan...
ASCO 2013: Dr. Kumar...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Weise...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Jagan...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Kumar...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Ghobr...
ASCO 2013: Dr. Lokho...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Richa...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Nooka...
ASCO 2013: Dr. Palum...
ASCO 2013: Dr. Raje ...
ASCO 2013: Dr. Pande...
"Understanding Healt...
Understanding Adhere...
Understanding Serum ...
Best of ASH 2013: Wh...
BLACK SWAN RESEARCH ...
BLACK SWAN RESEARCH ...

California Support G...
Cancer Awareness Bra...
Dr. Brian Durie, Cha...
IMF Nurse Leadership...
International Myelom...
International Myelom...
Mensajero del Mielom...
Michael and Robin Tu...
Pomalidomide News: P...
Raise Your Voice Web...
Sign up TODAY for Ad...
Supreme Court Uphold...
The International My...

ASCO 2013: Dr. Anderson - Overview of the 2013 Annual Meeting of the American Society of Clinical Oncology
ASCO 2013: Dr. Jagannath - Data on New Novel Agents
ASCO 2013: Dr. Kumar - Emerging Trends for Multiple Myeloma Patient Survival
ASCO 2013: Dr. Lonial - Overview of New Novel Agents Presented at ASCO 2013
ASCO 2013: Dr. Richardson - Current Front Line Treatments
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
ASCO 2013: Dr. Palumbo - Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Kumar- Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.
ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM
ASCO 2013: Dr. Lokhorst - Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).
ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
ASCO 2013: Dr. Raje - Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
"Understanding Health Disparities in Cancer: The Case of Multiple Myeloma"
Understanding Adherence to Oral Cancer Therapy
Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays
Best of ASH 2013: What Patients Need to Know
BLACK SWAN RESEARCH INITIATIVE™ DONOR LEVELS
BLACK SWAN RESEARCH INITIATIVE™ MEDIA CONTACT
BRAZIL WORKSHOP
California Support Group Leader’s Testimony Makes Huge Difference
Cancer Awareness Bracelets
Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
International Myeloma Foundation (IMF)
Flow Workshop Presentations
July 18-19, 2014
International Myeloma Foundation Mission Statement
Mensajero del Mieloma - Otoño 2012 - #903
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
Pomalidomide News: Promising Results Increase Chances of Early Drug Approval
Raise Your Voice Web Series
Sign up TODAY for Advocacy Training Two-Part Online Series!
Supreme Court Upholds Affordable Care Act
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law


You might also be interested in:

Overviews
ASCO 2013: Dr. Anderson - Overview of the 2013 Annual Meeting of the American Society of Clinical Oncology

Ken Anderson, MD
Dana Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Jagannath - Data on New Novel Agents

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA


ASCO 2013: Dr. Kumar - Emerging Trends for Multiple Myeloma Patient Survival

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA


ASCO 2013: Dr. Lonial - Overview of New Novel Agents Presented at ASCO 2013

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - Current Front Line Treatments

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Immunomodulatory Agents
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).

Katja Weisel, MD
University Hospital Tuebingen
Tuebingen, Germany


ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA


ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.

Antonio Palumbio, MD
University Of Turin
Turin, Italy


ASCO 2013: Dr. Palumbo - Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).

Antonio Palumbio, MD
University Of Turin
Turin, Italy


ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA


Proteasome Inhibitors
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA


ASCO 2013: Dr. Kumar- Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA


ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Other Novel Agents
ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA


ASCO 2013: Dr. Lokhorst - Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.

Henk M. Lokhorst, MD
University Medical Center Utrecht
Utrecht, Netherlands
Member, IMF Board of Scientific Advisors


ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA


ASCO 2013: Dr. Richardson - Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


Transplant
ASCO 2013: Dr. Usmani - Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).

Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Little Rock, Arkansa, USA


ASCO 2013: Dr. Nooka- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).

Ajay Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA


ASCO 2013: Dr. Palumbo - Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.

Antonio Palumbio, MD
University Of Turin
Turin, Italy


Others
ASCO 2013: Dr. Raje - Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.

Noopur Raje, MD
Massachusetts General Hospital
Boston, Massachusetts, USA


ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.

Shivlal Pandey, MD
Mayo Clinic
Rochester, Minnesota, USA